The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome
Open accessAbstract
BACKGROUND & AIMS: Type 1 hepatorenal syndrome (HRS) is the most high‐risk type of renal failure in patients with cirrhosis. Terlipressin and albumin are effective treatments for type 1 HRS. However, the effects of acute on chronic liver failure (ACLF) grade on response to treatment are not clear. We aimed to identify factors associated with response to treatment with terlipressin and albumin in patients with type 1 HRS (reduction in serum level of creatinine to below 1.5 mg/dL at the end of treatment) and factors associated with death within 90 days of HRS diagnosis (90‐day mortality). METHODS: We performed a retrospective analysis of 4 different cohorts of consecutive patients with HRS treated with terlipressin and albumin from February 2007 through January 2016 at medical centers in Europe (total, 298 patients). We analyzed demographic, clinical, and laboratory data collected before and during treatment; patients were followed until death, liver transplantation, or 90 days after HRS diagnosis. RESULTS: Response to treatment was observed in 53% of patients. Of patients with grade 1 ACLF, 60% responded to treatment; among those with grade 2 ACLF, 48% responded, and among those with grade 3 ACLF, 29% responded (P < .001 for comparison between grades). In multivariate analysis, baseline serum level of creatinine (odds ratio, 0.23; P = .001) and ACLF grade (odds ratio, 0.63; P = .01) were independently associated with response to treatment. Patient age (hazard ratio [HR], 1.05; P < .001), white blood cell count (HR, 1.51; P = .006), ACLF grade (HR, 2.06; P < .001), and no response to treatment (HR, 0.41; P < .001) associated with 90‐day mortality. CONCLUSION: In a retrospective analysis of data from 4 cohorts of patients treated for type 1 HRS, we found ACLF grade to be the largest determinant of response to terlipressin and albumin. ACLF grade affects survival independently of response to treatment. New therapeutic strategies should be developed for patients with type 1 HRS and extrarenal organ failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Cited by
Guidelines on the management of ascites in cirrhosis
Aithal, G. P., Palaniyappan, N., China, L., Härmälä, S., Macken, L., Ryan, J. M., Wilkes, E. A., Moore, K., Leithead, J. A., Hayes, P. C., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321790 · Cited by 680
Acute-on-Chronic Liver Failure
Arroyo, V., Moreau, R., & Jalan, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1914900 · Cited by 650
Self-citationArroyo, V., Angeli, P., Moreau, R., Jalan, R., Clària, J., Trebicka, J., Fernández, J., Gustot, T., Caraceni, P., & Bernardi, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.048 · Cited by 458
Self-citationCirrhosis-associated immune dysfunction
Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., & Álvarez-Mon, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00520-7 · Cited by 447
Angeli, P., Garcia-Tsao, G., Nadim, M. K., & Parikh, C. R. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.002 · Cited by 432
Self-citationDysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango
Martin-Mateos, R., Alvarez-Mon, M., & Albillos, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00973 · Cited by 116
Solà, E., Pose, E., Campion, D., Piano, S., Roux, O., Simon-Talero, M., Uschner, F., de Wit, K., Zaccherini, G., Alessandria, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.009 · Cited by 41
“119 In fact, patients with the most severe ACLF, namely ACLF grades 2 and 3 (2 or 3+ organ failures, respectively), had a lower probability of response to terlipressin and albumin compared to patients with ACLF grade 1.”
Self-citationAcute-on-chronic liver failure: Objective admission and support criteria in the intensive care unit
Dong, V., & Karvellas, C. J. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.005 · Cited by 38
Metadata
- Authors
- Piano, S., Schmidt, H. H., Ariza, X., Amoros, A., Romano, A., Hüsing-Kabar, A., Solà, E., Gerbes, A., Bernardi, M., Alessandria, C., Scheiner, B., Tonon, M., Maschmeier, M., Solè, C., Trebicka, J., Gustot, T., Nevens, F., Arroyo, V., Gines, P., & Angeli, P.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 16
- Issue
- 11
- Pages
- 1792-1800.e3
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2791655479
- Cited by
- 173
- References
- 1
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.